OBJECTIVES: To determine the role of preoperative pulmonary function tests (PFTs) in patients with aortic stenosis (AS) evaluated for aortic valve replacement (AVR), and to evaluate the association between lung disease and mortality in specific subgroups. METHODS: Between 2008 and 2013, 535 patients with preoperative PFTs underwent AVR (transcatheter AVR [TAVR], n = 246; surgical AVR [SAVR], n = 289). The severity of lung disease determined by the Society of Thoracic Surgeons (STS) definition was evaluated in those with and without a clinical suspicion for lung disease (smoking, inhaled steroids/bronchodilators, or home oxygen). The association between lung disease and 1-year mortality was evaluated. RESULTS: Of the 186 patients (35%) without suspected lung disease, 39 (21%) had moderate/severe lung disease by PFT analysis. Among all patients, 1-year mortality was 12% in those with no lung disease, 17% in those with no mild lung disease, 22% in those with moderate lung disease, and 31% in those with severe lung disease (P < .001, log-rank test). After adjustment, moderate/severe lung disease was associated with increased 1-year mortality (adjusted hazard ratio, 2.07; 95% confidence interval, 1.30-3.29; P = .002); this association was not altered by smoking history, suspicion of lung disease, New York Heart Association class, or AVR type (interaction P value nonsignificant for all). CONCLUSIONS: In patients with AS evaluated for AVR, the STS risk score is significantly influenced by the severity of lung disease, which is determined predominantly by PFT results. Even when lung disease is not suspected, PFTs are abnormal in many patients undergoing AVR. Moderate/severe lung disease, diagnosed predominantly by PFTs, is an independent predictor of mortality after SAVR or TAVR. Collectively, these findings suggest that PFTs should be a routine part of the risk stratification of patients considered for AVR.
OBJECTIVES: To determine the role of preoperative pulmonary function tests (PFTs) in patients with aortic stenosis (AS) evaluated for aortic valve replacement (AVR), and to evaluate the association between lung disease and mortality in specific subgroups. METHODS: Between 2008 and 2013, 535 patients with preoperative PFTs underwent AVR (transcatheter AVR [TAVR], n = 246; surgical AVR [SAVR], n = 289). The severity of lung disease determined by the Society of Thoracic Surgeons (STS) definition was evaluated in those with and without a clinical suspicion for lung disease (smoking, inhaled steroids/bronchodilators, or home oxygen). The association between lung disease and 1-year mortality was evaluated. RESULTS: Of the 186 patients (35%) without suspected lung disease, 39 (21%) had moderate/severe lung disease by PFT analysis. Among all patients, 1-year mortality was 12% in those with no lung disease, 17% in those with no mild lung disease, 22% in those with moderate lung disease, and 31% in those with severe lung disease (P < .001, log-rank test). After adjustment, moderate/severe lung disease was associated with increased 1-year mortality (adjusted hazard ratio, 2.07; 95% confidence interval, 1.30-3.29; P = .002); this association was not altered by smoking history, suspicion of lung disease, New York Heart Association class, or AVR type (interaction P value nonsignificant for all). CONCLUSIONS: In patients with AS evaluated for AVR, the STS risk score is significantly influenced by the severity of lung disease, which is determined predominantly by PFT results. Even when lung disease is not suspected, PFTs are abnormal in many patients undergoing AVR. Moderate/severe lung disease, diagnosed predominantly by PFTs, is an independent predictor of mortality after SAVR or TAVR. Collectively, these findings suggest that PFTs should be a routine part of the risk stratification of patients considered for AVR.
Authors: Martin B Leon; Craig R Smith; Michael Mack; D Craig Miller; Jeffrey W Moses; Lars G Svensson; E Murat Tuzcu; John G Webb; Gregory P Fontana; Raj R Makkar; David L Brown; Peter C Block; Robert A Guyton; Augusto D Pichard; Joseph E Bavaria; Howard C Herrmann; Pamela S Douglas; John L Petersen; Jodi J Akin; William N Anderson; Duolao Wang; Stuart Pocock Journal: N Engl J Med Date: 2010-09-22 Impact factor: 91.245
Authors: Neil E Moat; Peter Ludman; Mark A de Belder; Ben Bridgewater; Andrew D Cunningham; Christopher P Young; Martyn Thomas; Jan Kovac; Tom Spyt; Philip A MacCarthy; Olaf Wendler; David Hildick-Smith; Simon W Davies; Uday Trivedi; Daniel J Blackman; Richard D Levy; Stephen J D Brecker; Andreas Baumbach; Tim Daniel; Huon Gray; Michael J Mullen Journal: J Am Coll Cardiol Date: 2011-10-20 Impact factor: 24.094
Authors: Craig R Smith; Martin B Leon; Michael J Mack; D Craig Miller; Jeffrey W Moses; Lars G Svensson; E Murat Tuzcu; John G Webb; Gregory P Fontana; Raj R Makkar; Mathew Williams; Todd Dewey; Samir Kapadia; Vasilis Babaliaros; Vinod H Thourani; Paul Corso; Augusto D Pichard; Joseph E Bavaria; Howard C Herrmann; Jodi J Akin; William N Anderson; Duolao Wang; Stuart J Pocock Journal: N Engl J Med Date: 2011-06-05 Impact factor: 91.245
Authors: Corrado Tamburino; Davide Capodanno; Angelo Ramondo; Anna Sonia Petronio; Federica Ettori; Gennaro Santoro; Silvio Klugmann; Francesco Bedogni; Francesco Maisano; Antonio Marzocchi; Arnaldo Poli; David Antoniucci; Massimo Napodano; Marco De Carlo; Claudia Fiorina; Gian Paolo Ussia Journal: Circulation Date: 2011-01-10 Impact factor: 29.690
Authors: A Selcuk Adabag; Heba S Wassif; Kathryn Rice; Salima Mithani; Deborah Johnson; Jana Bonawitz-Conlin; Herbert B Ward; Edward O McFalls; Michael A Kuskowski; Rosemary F Kelly Journal: Am Heart J Date: 2010-04 Impact factor: 4.749
Authors: Michael Mok; Luis Nombela-Franco; Eric Dumont; Marina Urena; Robert DeLarochellière; Daniel Doyle; Jacques Villeneuve; Mélanie Côté; Henrique B Ribeiro; Ricardo Allende; Jerôme Laflamme; Hugo DeLarochellière; Louis Laflamme; Ignacio Amat-Santos; Philippe Pibarot; François Maltais; Josep Rodés-Cabau Journal: JACC Cardiovasc Interv Date: 2013-10 Impact factor: 11.195
Authors: Rebecca L Gunter; Patrick Kilgo; Robert A Guyton; Edward P Chen; John D Puskas; William A Cooper; Michael E Halkos; Omar M Lattouf; Vasilis Babaliaros; Richard Myung; Bradley Leshnower; Vinod H Thourani Journal: Ann Thorac Surg Date: 2013-08-20 Impact factor: 4.330
Authors: Mitchell J Magee; Morley A Herbert; Karen L Roper; Elizabeth Holper; Todd M Dewey; Tricia Snelus; Michael J Mack Journal: Ann Thorac Surg Date: 2013-07-25 Impact factor: 4.330
Authors: James M Brown; Sean M O'Brien; Changfu Wu; Jo Ann H Sikora; Bartley P Griffith; James S Gammie Journal: J Thorac Cardiovasc Surg Date: 2009-01 Impact factor: 5.209
Authors: Cheng Ting Lin; Matthew J Czarny; Amira Hussien; Rani K Hasan; Brian T Garibaldi; Elliot K Fishman; Jon R Resar; Stefan Loy Zimmerman Journal: Radiol Cardiothorac Imaging Date: 2020-04-30
Authors: M S van Mourik; J F Velu; V R Lanting; J Limpens; B J Bouma; J J Piek; J Baan; J P S Henriques; M M Vis Journal: Neth Heart J Date: 2020-05 Impact factor: 2.380